Apremilast - Oral Lichen Planus Trial

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 21, 2019

Primary Completion Date

April 22, 2020

Study Completion Date

April 22, 2020

Conditions
Oral Lichen Planus
Interventions
DRUG

Apremilast

Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.

DRUG

Placebo

Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.

Trial Locations (1)

M4N3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Sunnybrook Research Institute

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER

NCT03836885 - Apremilast - Oral Lichen Planus Trial | Biotech Hunter | Biotech Hunter